3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition.
3,4-methylenedioxyamfetamine (MDMA, ecstasy) use reduces cognition by reducing levels of dopamine and serotonin in the central nervous system. This results in dose-related cognition impairment, particularly in complex cognitive skills, as well as causing disorders such as mood changes, hallucinations, altered perception amd memory loss. MDMA reduces the level of these neurotransmitters within the neural synapses by reducing the number of intraneural transporters to the synaptic clefts, increasing deactivation with the synapse and/ or increasing degradation with the pre- and postsynaptic neurons. Users may have varied reasons for MDMA use and therefore require help and support from their families or friends, and knowledgeable and well-skilled healthcare professionals for successful abstinence, avoidance of further psychological damage and a reversal of adverse health effects or reduction in their severity.
Chummun
Harry
H
School of Health and Social Care, University of Greenwich, London.
Tilley
Victoria
V
Ibe
Jude
J
D000818:Animals; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000139:chemically induced* / Q000451:nursing*; D006801:Humans; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000633:toxicity*
D018817:N-Methyl-3,4-methylenedioxyamphetamine